50 of the Top 250 law firms use our Products every day
Exhibit 10.30
November 11, 2005
Bayer Pharmaceuticals
Corporation
400 Morgan Lane
West Haven, CT 06516-4175
ATTN: Legal Department
Gentlemen:
Reference is made to the Metabolic
Disorder Collaboration Agreement dated January 12, 2001
between Bayer Corporation and CuraGen Corporation (as previously
amended, the “Agreement”). Terms which are defined in
the Agreement are used herein as so defined. This letter will set
forth our agreement with respect to an amendment of the
Agreement.
|
|
1.
|
Notwithstanding
the provisions of Section 4.1(a)(iii) or any other provision
of the Agreement, effective October 31, 2005 CuraGen shall not
bear any further Development Costs of the Metabolic Program
relating to the Pre-Clinical Development Phase, Clinical
Development Phase and/or Commercialization Phase with respect to
the Development Compound known as CT052 and any Metabolic Program
Drug developed from such Development Compound. Pursuant to
Section 2.4(e), CuraGen will, following October 31, 2005,
no longer have any representatives on the
|
|
